文章
醫療新知 > Cellink以3D列印製造腫瘤以對抗癌症 / Cellink Turns to 3D Printing Tumors to Combat Cancer

Cellink以3D列印製造腫瘤以對抗癌症 / Cellink Turns to 3D Printing Tumors to Combat Cancer

24-01-2018

Cellink以3D列印製造腫瘤以對抗癌症

陳智德

 

 

 

Cellink希望能夠用實驗用腫瘤取代大量的動物測試。Cellink

 

 

 

瑞典生物科技公司Cellink設計出生物墨水(biological ink),可被各種不同3D列印機用於製造不同種類的細胞組織,目前正研究以3D列印製造腫瘤以對抗癌症。此將能看到實際上腫瘤如何生長,以及如何對不同治療做出反應。

 

 

Cellink的最新活動已引發3D列印界內外的極大興趣。該公司日前宣布,已與法國公司CTI Biotech簽署合作協議,製造可用於藥品檢測的腫瘤。透過將生物墨水與病患癌細胞混合的方式,在不危害人體健康下進行對腫瘤的深入研究。

 

 

目前Cellink生產生物列印的鼻子及耳朵,用於化妝品與醫學研究,並製造由人體器官細胞組成的立方體,讓研究人員對進行實驗。

 

 

製造新藥對抗癌症既是公眾的優先考慮,但因癌症細胞存活於病患體內,病患並非皆能接受試驗性地服用新藥對抗癌症,使得新藥發展緩慢,並可能會扼殺創新概念,或為他人的進展製造障礙,因此製造用於藥品檢測的腫瘤擁有深遠的意義。

 

 

Cellink盼未來能列印人體器官,儘管該公司承認可能還要再等15~20年。使用生物墨水製造的腫瘤進行測試,能讓研究人員擺脫許多道德問題,並降低此類研究活動的相關成本。

 

 

Cellink希望能夠用實驗用腫瘤取代大量的動物測試,不僅可開發處理癌症腫瘤的新方式,且能讓醫學研究人員對個人化的癌症治療方法展開研究,減少治療造成的副作用。

 

 

該公司創辦人Erik Gatenholm與Hector Martinez Avila也創造售價最低僅10,000美元的組織3D列印機,引發大量的需求。

 

 

 

Cellink Turns to 3D Printing Tumors to Combat Cancer

by | Jan 9, 2018 | 3D Printing, Medical 3D Printing, Science & Technology |

 
 
It may seem counterintuitive, but the Swedish biotech company Cellink is actually fabricating tumors in an effort to combat cancer. The company, which exploded on the scene in 2016, has risen to fame as a result of their biological ink, designed to be used by a variety of 3D printers to create different types of cell tissues. The founders, Erik Gatenholm and Hector Martinez Avila, then went on to create a tissue printing 3D printer that sells for only $10k and the demand has been phenomenal.
 
 
 
The market for bioprinting is expected to triple between 2016 and 2021, to around $1,33 bn.
[Image courtesy of Cellink]
 
 
 

The company has been in the news so often, it’s nearly exhausting trying to keep up, but their latest activity is one that has garnered great interest both in and outside of the 3D printing community. The company announced on Monday that they have signed a partnership with CTI Biotech, a French company based in Lyon, to fabricate tumors that can be used for pharmaceuticals testing. The ability to mix their own inks with cells from patients’ cancers will allow them to produce tumors that can be subjected to intense research without endangering human lives. As Gatenholm explained in an interview with Business Insider Nordic:

 

 

“You will be able to see how a tumor grows and how it would respond to different treatments. It’s a very relevant and a realistic model for research.”

 

 

Cellink sells both the 3D printers and the bio-ink. The printers are priced between $10,000 and $39,000. [Image courtesy of Cellink]

 

 

 

Currently, Cellink produces bioprinted noses and ears for cosmetics and medical research, as well as creating cubes comprised of cells that can allow researchers to experiment with human organ cells. Branching out into the production of tumors is less of a leap and more of an expansion, and the implications are profound. Developing new medicines to combat cancer is both a high priority for the public and something that can only necessarily proceed slowly as the cancer itself lives inside of a person, who cannot simply be subject to any and all ideas about what might combat the disease. This means that a slow, cautious approach can strangle some innovative ideas or simply create interminable roadblocks to the advancement of others.

 

The ability to use bioink to create tumors frees researchers of the many ethical concerns associated with testing as well as reduces the costs associated with such research activities. Currently, a great deal of the medical testing being undertaken to advance cancer treatments occurs on animals, something that Cellink hopes will be able to be replaced with these made-in-the-lab tumors. The driving idea is that not only will new methods of addressing cancerous tumors be able to be developed, but that also medical researchers can begin to explore personalized means of delivering cancer treatments, hopefully with fewer negative side effects.

 

 

 

Cellink’s founders Hector Martinez Avila (left) and Erik Gatenholm (right), with Cellink CCO Ariel Kramer at Nasdaq First North for the IPO. [Image courtesy of Business Insider Nordic]

 

 

 

This effort is part of Cellink’s mission to be a global leader in bioprinting and to change the face of medicine as we know it. In addition, they hope to one day be able to print human organs, although, Gatenholm admits, that possibility is still most likely 15 to 20 years in the future. Interest in their ideas has been strong and confidence in their company continues to grow, as demonstrated by the fact that only 10 months after the company was founded, there was a 1000% oversubscription to their IPO. During their first year, they have already reached profitability, something not common for tech startups.

 

What do you think of this news? Let us know your thoughts; join the discussion of this and other 3D printing topics at 3DPrintBoard.com or share your thoughts below.

 

 

 

文章來自: 物聯網 – 智慧城市 / 3Dprint.com

中: https://www.digitimes.com.tw/iot/article.asp?cat=158&id=0000522680_X9U7ROVH7DAP4D1R7EOV4

ENG : https://3dprint.com/199654/cellink-3d-printing-tumors/

城中活動

2024-04-12 9:00 上午 小帆船體驗
2024-03-11 10:30 上午 2024人像攝影工作坊

疑難排解

會員註冊


或許你會想看
首間港資深圳私人綜合醫院 盼縮短港人治療輪候時間
本港公營醫療服務供不應求,導致病人長期輪候成常態。近期港人流行「北上消費」,除了吃喝玩樂,「北上醫療」亦是「北 […]
深圳新風和睦家醫院與保誠保險簽署跨境保險業務合作,進一步拓展大灣區醫療網絡服務
深圳新風和睦家醫院(以下簡稱「和睦家」)與保誠保險有限公司(以下簡稱「保誠」)今日簽署戰略性的直接合作,保誠成 […]
中大開發與多種癌症相關的纖維母細胞分子分類方法 助進一步了解癌症進展並改良治療方案
・中大醫學院研究團隊最近識別出四種與癌症相關的纖維母細胞分子聚集,大大促進對複雜腫瘤微環境的理解。 ・這項突破 […]
政府公布「長者醫療券大灣區試點計劃」醫療機構名單(附圖)
政府今日(二月十九日)公布把七間位於粵港澳大灣區的醫療機構納入「長者醫療券大灣區試點計劃」,讓合資格的香港長者 […]
和黃醫藥宣布愛優特® (呋喹替尼) 於香港獲批用於治療轉移性結直腸癌
– 香港特區政府新的「1+」新藥審批機制下首個獲批在港註冊的藥物 ,為香港患者帶來重要的治療選擇 – – 愛優 […]
中大發現造血調節因子在腫瘤微環境的重要角色 為肺癌帶來新的治療靶點
肺癌是香港以至全球最致命的癌症之一,但目前缺乏有效的臨床治療。香港中文大學(中大)醫學院最新研究發現,肺癌能利 […]
肺癌治療新趨勢 術前加入免疫治療提升療效|心胸肺外科專科 薛高勇醫生
癌症是主要的疾病殺手之一,其中肺癌更一直蟬聯癌症殺手的首位。怎樣才能降低肺癌的殺傷力?其實只要愈早發現肺部病變 […]
全港首個中文版網上「前列腺癌監察計算機」 助前列腺癌患者自行監察病情進展 與醫生共商最佳治療方案
前列腺癌發病率不斷攀升,現時佔本港男性最常見的癌症中排第三位,以及在致命癌症中排第四位。猶幸近年前列腺癌的治療 […]
港大醫學院發現新靶點PLK4抑製劑有效治療TP53突變血癌 在瑪麗醫院及全球其他試點取證
香港大學李嘉誠醫學院(港大醫學院)臨床醫學學院內科學系梁如鴻教授領導的研究團隊,確定PLK4可作為一個全新的標 […]
大腸癌篩查計劃 | 1948-1974 出生香港居民 元旦起可參加大腸癌篩查計劃
衞生署今日(十二月二十八日)宣布,一九四八至一九七四年出生的香港居民,由明年一月一日起,符合資格參加大腸癌篩查 […]
中大醫學院證實以AI輔助大腸內窺鏡檢查 腺瘤檢測率增加四成 並成功訓練AI輔助早期消化道癌症治療
人工智能(AI)於醫學界的應用愈趨廣泛,香港中文大學(中大)醫學院最近就AI輔助內窺鏡技術完成兩項研究,均證實 […]
另闢途徑對抗胃腸道基質腫瘤 | 龍浩鋒醫生
胃癌、腸癌,大家都時有聽聞,但生長在腸胃道的腫瘤,還有一種相當罕見的胃腸道基質瘤(Gastrointestin […]